Microbiome drug reduces recurrent CDI

The investigational oral microbiome drug CP101 helped prevent recurrence of Clostridioides difficile infection across a broad population of patients, according to research presented at UEG Week Virtual.In her presentation, Jessica Allegretti, MD, from Brigham & Women’s Hospital, said recurrent CDI is associated with loss of microbiome diversity and impaired colonization resistance. CP101 (Finch Therapeutics) was designed to prevent that.“This oral agent was developed to restore a complete microbiome community with a systems biology approach directly mimicking underlying biology,”Read More

Share on facebook
Share on twitter
Share on linkedin